Miami (January 14, 2025) – People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study. The study is published in the November 2024 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.
Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema. Symptoms include breathlessness, fatigue and chronic cough. The disease affects more than 30 million Americans and is the fourth leading cause of death worldwide.
Previous research has shown that people with COPD have a higher risk of falling due to increased frailty, impaired gait and the tripping hazard of oxygen tubing. They also commonly experience pain, anxiety, insomnia and other comorbidities, such as diabetes or hypertension. Opioids, benzodiazepines and other medications used to treat these comorbidities and symptoms can increase a person’s risk of falling and fall-related injuries.
“Fall-risk increasing drugs are commonly prescribed to people with COPD because they experience a high number of symptoms and conditions that indicate use of these drugs,” said Cara L. McDermott, PharmD, PhD, assistant professor in medicine in the Division of Geriatrics and Palliative Care at Duke University School of Medicine and lead author of the study. “However, injuries from falls can lead to emergency department visits or hospitalization, resulting in a lower quality of life and increased health care costs.”
The study examined data from a single health system linked to Washington State death certificates of adults 40 or older with COPD who died between 2014 and 2018. Of the 8,204 people, 65% were prescribed at least one fall-risk increasing drug, and 30% had a fall with injury in the two years prior to their death.
“Our study compared the number of falls in the two years prior to death in people with COPD who used fall-risk increasing drugs to those with COPD who did not use these drugs. We found that the chance of a person falling increased relative to how many fall-risk increasing drugs they used,” Dr. McDermott said. “Pulmonologists and pharmacists need to collaborate with each other and with patients to develop fall prevention strategies and to increase patient safety by reducing the use of fall-risk increasing drugs and discussing other ways to mitigate fall risk.”
To access current and past issues of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, visit journal.copdfoundation.org.
###
About the COPD Foundation
The COPD Foundation is a nonprofit organization whose mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. The Foundation does this through scientific research, education, advocacy, and awareness to prevent disease, slow progression, and find a cure. For more information, visit copdfoundation.org, or follow us on Twitter and LinkedIn.
Journal
Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation
Article Title
Fall Risk and Medication Use Near End of Life Among Adults With Chronic Obstructive Pulmonary Disease
Article Publication Date
25-Oct-2024
COI Statement
CLM reports grant funding from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). She is a consultant for the nonprofit Biologics and Biosimilars Collective Intelligence Consortium and received honoraria from the University of Utah in 2023 for speaking at 2 departmental seminars. LCF received grant support from the Patient-Centered Outcomes Research Institute (PCORI), the American Lung Association, the Department of Veterans Affairs Health Systems Research, and the NIH/NHLBI. She has received travel funding from the American Thoracic Society to attend leadership meetings, and consultant fees from the Society of Hospital Medicine and the National Quality Assurance Committee. RAE received funding support from the Cambia Health Foundation. LJS reports grant support from the NIH/NHLBI. LD reports grant support from the Department of Veterans Affairs Health Systems Research and the PCORI, plus an honorarium from the American Academy of Sleep Medicine as a continuing medical education speaker for the 2023 conference. JRC received funding support from the Cambia Health Foundation.